Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India.

Revenue projections:

Revenue projections for APLLTD
Revenue projections for APLLTD

APLLTD's revenue is projected to decrease from last year, a development that could lead investors to adopt a more cautious approach. A revenue decline can negatively affect profitability, signaling challenges for the company and making it less attractive for those seeking solid financial performance.

Financial Ratios:

currentRatio 0.00000
forwardPE 17.65567
debtToEquity 28.00400
earningsGrowth -0.03600
revenueGrowth 0.10800
grossMargins 0.71510
operatingMargins 0.11372
trailingEps 32.05000
forwardEps 43.21841

Alembic Pharmaceuticals Limited's Forward PE being in a good range indicates that the stock is valued appropriately based on its earnings. This suggests the stock is not overpriced and leaves room for growth, providing investors with an opportunity for potential appreciation in value.
APLLTD's low Debt-to-Equity ratio indicates that the company isn't heavily dependent on debt financing. This lower leverage reduces financial risk and enhances stability, showing that APLLTD is well-positioned to manage its obligations without the burden of excessive debt.
APLLTD's low growth in both earnings and revenue signals a potential profit decline. This could be a sign of financial trouble, suggesting that the company's profitability might shrink in the near future.
With negative gross and operating margins, APLLTD is facing losses at both the production and operational levels. This signals significant financial strain and may indicate that the company is struggling to manage costs effectively.
Alembic Pharmaceuticals Limited's forward EPS exceeding its trailing EPS reflects expectations of increased profitability for the current year. This suggests that the company is projected to achieve higher earnings than in the previous financial year, signaling positive growth and improved financial health.

Price projections:

Price projections for APLLTD
Price projections for APLLTD

APLLTD's current price shows alignment with projections, offering no clear risks or opportunities. This neutral stance indicates a stable market environment, where investors may prefer to maintain their positions until more compelling information surfaces.

Insider Transactions:

Insider Transactions for APLLTD
Insider Transactions for APLLTD


Alembic Pharmaceuticals Limited saw 20 transactions to buy shares, with a market price of 881.7800018310547.There were no buy transactions throughout the period under consideration.The ongoing selling activity at APLLTD's current price levels suggests a potential risk of further declines. If more investors continue to sell, this trend could lead to continued downward pressure on the stock's price.

Recommendation changes over time:

Recommendations trend for APLLTD
Recommendations trend for APLLTD


Analysts are favoring Alembic Pharmaceuticals Limited with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider Alembic Pharmaceuticals Limited as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.